SOURCE: Xtalks

Xtalks Webinars

May 17, 2017 07:30 ET

5 Qualities to Consider When Selecting Clinical Pharmacology Units for Early Drug Development, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - May 17, 2017) - On June 6, 2017 industry expert Jon Rojas, CEO of WCCT Global will discuss five qualities shared by successful clinical pharmacology units for Early Clinical Development. Additionally, he will discuss the ways in which sponsors and CROs can begin proactively encouraging their pre-approved Phase 1 sites to engage in these measures and incorporate them as standard operating procedures, ensuring that clinical pharmacology units are offering the highest value possible to their clients while still maintaining quality and safety during the conduct of any early phase clinical program. Sponsors and CROs can utilize this information and set expectations for the selection of new sites to be added to their shortlists.

When it comes to selecting clinical pharmacology units for Early Clinical Development, oftentimes Sponsors and CROs are only concerned with selecting units with large bed capacity and high-volume enrollment capabilities. While fulfilling these conditions are typically the most imperative when selecting a clinical pharmacology unit, there are several additional vital qualities that are shared by high-performing clinical pharmacology units which should be considered. Typically, items such as internal costing exercises, staff optimization, vendor management and selection, procedural capabilities, and safety measures are of top considerations to the conduct of most early development programs.

Coming from a both a CRO and clinical pharmacology unit perspective, WCCT Global offers insight into the five qualities that are most indicative of a high-performing, optimized Phase 1 site. Having these qualities can serve to offer Sponsors significant benefits beyond large bed capacity and high-volume enrollment, such as substantial cost savings, guaranteed risk mitigation and contingency planning, and the ability to execute various protocol requirements in the most economic yet efficient way possible.

Mr. Rojas will present a recent WCCT Global case study demonstrating the tactics and strategies that can be requested by sponsor companies and implemented by Phase 1 sites to fit into the emerging paradigm of the full-service, high-performing clinical pharmacology units which are being sought after by companies still investing heavily in early clinical development in normal healthy volunteers and special patient populations.

Join Jon Rojas on Tuesday, June 6, 2017 at 2pm EDT. For more information or to register for this complimentary event, visit: 5 Qualities to Consider When Selecting Clinical Pharmacology Units for Early Drug Development

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit: http://xtalks.com

For information about hosting a webinar visit: http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2017/5/16/11G139044/Images/medelis-wcct-2017-FULLCOLOR-transparent_400-b3f9fb1d5ae09714bb0477a0b079aa26.jpg

Contact Information